Euglycem® plus recommended diet to lower blood sugar in people with dysglycemia
Official title: Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Euglycem in Reducing Blood Glucose in Patients With Dysglycemia After Three Months of Treatment - EUGLYCARE Study
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07263789 · Data updated 2026-11-12
This will see if taking the supplement Euglycem® alongside a recommended diet lowers fasting blood sugar after three months in adults with dysglycemia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 108 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 2 sites (Pavia, Lombardy and 1 other locations) |
| Status | Recruiting |
| Started | April 8, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | January 31, 2026 |
| Registry record updated | December 4, 2025 |
| Trial ID | NCT07263789 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with dysglycemia (prediabetes), BMI ≤30 kg/m2, able to consent and willing to follow the diet and study visits are the ideal candidates.
✕Probably not a fit
People already taking drugs that affect blood glucose, those with BMI >30, or those enrolled in another investigational trial are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with dysglycemia and BMI ≤30 will follow a recommended standard diet and receive either Euglycem® or a placebo for three months. The main measure is change in fasting plasma glucose from baseline to three months. Participants taking medications that affect blood glucose or currently enrolled in other investigational drug/device trials are excluded. Study visits take place at the IRCCS Policlinico San Matteo in Pavia, Italy.
Why it matters
Potential benefit: If successful, this could help lower fasting blood sugar and potentially reduce the risk of progressing to type 2 diabetes.
How similar studies have gone: Similar nutraceutical approaches have shown mixed results in small trials, with some modest glucose-lowering effects but overall limited and inconsistent evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI ≤30 kg/m2 * subjects able to understand the informed consent and sign it before enrollment in the study * subjects willing to follow all study requirements and perform all study visits as well as collaborate with the investigator. Exclusion Criteria: * ongoing treatment with drugs that can affect blood glucose * current participation in another investigational drug or investigational device trial or inclusion in another investigational drug or investigational device trial within the previous month
Where it's running
-
IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy Recruiting -
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, Italy Not yet recruiting
Study contacts
- Study coordinator: Giuseppe Derosa, MD
- Email: g.derosa@smatteo.pv.it
- Phone: +390382502614
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating brain health in youth at risk for type 2 diabetes
This study is trying to see how being overweight or having blood sugar issues affects brain health in kids aged 12-17 who might be at risk for type 2 diabetes.
-
Registry of patients with diabetes and those at risk of developing it
This study is creating a registry of people with diabetes, those at risk for it, and healthy individuals to see how their health data can help improve care recommendations.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.